All in all, in addition to all of the above, the fact that we did not analyze the studies that compared the effects of these GLP-1 agonists with the already-present standard of care used in the management of heart failure, such as angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, etc., shines a light on the limitations of our study. Here, GLP1R is linked to heart failure.